EA201490077A1 - N-(6-((2r,3s)-3,4-дигидроксибутан-2-илокси)-2-(4-фторбензилтио)пиримидин-4-ил)-3-метилазетидин-1-сульфонамид в качестве модуляторов рецептора хемокина - Google Patents

N-(6-((2r,3s)-3,4-дигидроксибутан-2-илокси)-2-(4-фторбензилтио)пиримидин-4-ил)-3-метилазетидин-1-сульфонамид в качестве модуляторов рецептора хемокина

Info

Publication number
EA201490077A1
EA201490077A1 EA201490077A EA201490077A EA201490077A1 EA 201490077 A1 EA201490077 A1 EA 201490077A1 EA 201490077 A EA201490077 A EA 201490077A EA 201490077 A EA201490077 A EA 201490077A EA 201490077 A1 EA201490077 A1 EA 201490077A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
pyrymidin
fluorbenzyltiho
iloxi
dihydroxybutan
Prior art date
Application number
EA201490077A
Other languages
English (en)
Other versions
EA027821B1 (ru
Inventor
Стивен Коннолли
Марк Ричард Ибден
Томас Лэнджер
Алан Роберт Стивен
Крейг Роберт Стюарт
Паула Маргарет Томлин
Айан Аластер Стюарт Уолтерс
Эндрю Джон Уилльямс
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201490077A1 publication Critical patent/EA201490077A1/ru
Publication of EA027821B1 publication Critical patent/EA027821B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/20—Free hydroxyl or mercaptan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/78—Benzoic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms

Abstract

Предложено соединение, представляющее собой (а) пиримидинсульфонамид формулы (I) или (б) его фармацевтически приемлемую соль, кристаллические формы данного соединения, способы получения данного соединения, фармацевтические промежуточные соединения, используемые в получении данного соединения, и фармацевтические композиции, содержащие данное соединение. Указанное соединение полезно в лечении заболевания/состояния, при котором полезно модулирование активности рецептора хемокинов.
EA201490077A 2011-07-12 2012-07-10 N-(6-((2r,3s)-3,4-дигидроксибутан-2-илокси)-2-(4-фторбензилтио)пиримидин-4-ил)-3-метилазетидин-1-сульфонамид в качестве модулятора рецептора хемокина EA027821B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161506737P 2011-07-12 2011-07-12
PCT/GB2012/051620 WO2013008002A1 (en) 2011-07-12 2012-07-10 N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator

Publications (2)

Publication Number Publication Date
EA201490077A1 true EA201490077A1 (ru) 2014-10-30
EA027821B1 EA027821B1 (ru) 2017-09-29

Family

ID=46513787

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490077A EA027821B1 (ru) 2011-07-12 2012-07-10 N-(6-((2r,3s)-3,4-дигидроксибутан-2-илокси)-2-(4-фторбензилтио)пиримидин-4-ил)-3-метилазетидин-1-сульфонамид в качестве модулятора рецептора хемокина

Country Status (37)

Country Link
US (3) US8735413B2 (ru)
EP (2) EP3255043B1 (ru)
JP (2) JP6006308B2 (ru)
KR (1) KR101946664B1 (ru)
CN (1) CN103781781B (ru)
AR (2) AR087168A1 (ru)
AU (2) AU2012282316B2 (ru)
BR (1) BR112014000636B1 (ru)
CA (1) CA2841859C (ru)
CL (1) CL2014000079A1 (ru)
CO (1) CO6852072A2 (ru)
CR (1) CR20140007A (ru)
CU (2) CU24292B1 (ru)
CY (1) CY1124329T1 (ru)
DK (1) DK3255043T3 (ru)
DO (1) DOP2013000308A (ru)
EA (1) EA027821B1 (ru)
EC (1) ECSP14013130A (ru)
ES (1) ES2861927T3 (ru)
HK (1) HK1245779A1 (ru)
HR (1) HRP20210413T1 (ru)
HU (1) HUE053703T2 (ru)
IL (1) IL230398A (ru)
LT (1) LT3255043T (ru)
MX (2) MX342874B (ru)
MY (1) MY180039A (ru)
NI (1) NI201400002A (ru)
PE (2) PE20181069A1 (ru)
PL (1) PL3255043T3 (ru)
PT (1) PT3255043T (ru)
RS (1) RS61608B1 (ru)
SG (1) SG10201605619XA (ru)
SI (1) SI3255043T1 (ru)
TW (2) TWI659026B (ru)
UY (1) UY34191A (ru)
WO (1) WO2013008002A1 (ru)
ZA (1) ZA201401059B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2593448A1 (en) 2010-07-13 2013-05-22 AstraZeneca AB New cristalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3- dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
MX342874B (es) * 2011-07-12 2016-10-17 Astrazeneca Ab N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pi rimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina.
EP2740458B1 (en) * 2012-12-06 2016-08-03 IP Gesellschaft für Management mbH Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide
BR112018068393A2 (pt) * 2016-03-11 2019-01-15 Ardea Biosciences Inc inibidores de cxcr-2 para o tratamento de distúrbios de artropatia por cristais
EP3681861A4 (en) * 2017-09-12 2021-06-09 Ardea Biosciences, Inc. CXCR-2 INHIBITORS FOR THE TREATMENT OF DISORDERS
JP7355858B2 (ja) * 2019-06-12 2023-10-03 ヌーリオン ケミカルズ インターナショナル ベスローテン フェノーツハップ 水性側流からカルボン酸を単離するための方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3457278A (en) * 1964-10-15 1969-07-22 Geigy Chem Corp Cyclopropyl-4-sulfanilamido-pyrimidines
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
FI981521A0 (fi) * 1998-07-01 1998-07-01 Orion Corp Substituoidut beta-diketonit ja niiden käyttö
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CA2406979A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
GB0419235D0 (en) * 2004-08-28 2004-09-29 Astrazeneca Ab Compounds
EP2311827A1 (en) * 2004-08-28 2011-04-20 AstraZeneca AB Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators.
CA2637631C (en) * 2006-01-19 2014-04-29 Orchid Research Laboratories Limited Pyrimidine compounds and uses thereof
WO2008157273A1 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
CN102159555A (zh) * 2008-07-16 2011-08-17 阿斯利康(瑞典)有限公司 嘧啶基氨磺酰衍生物及其治疗趋化因子介导的疾病的用途
CN102105434A (zh) 2008-07-25 2011-06-22 巴斯夫欧洲公司 3-氨基甲基-1-环己基胺及其生产方法
EP2593448A1 (en) * 2010-07-13 2013-05-22 AstraZeneca AB New cristalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3- dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
MX342874B (es) * 2011-07-12 2016-10-17 Astrazeneca Ab N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pi rimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina.

Also Published As

Publication number Publication date
US20140228339A1 (en) 2014-08-14
KR101946664B1 (ko) 2019-02-11
US9221782B2 (en) 2015-12-29
PT3255043T (pt) 2021-03-29
BR112014000636A2 (pt) 2017-01-10
LT3255043T (lt) 2021-04-12
JP6261666B2 (ja) 2018-01-17
US20160108023A1 (en) 2016-04-21
WO2013008002A1 (en) 2013-01-17
CU24292B1 (es) 2017-12-08
EP3255043A3 (en) 2018-04-18
HRP20210413T1 (hr) 2021-05-14
AU2016244246B2 (en) 2017-11-23
CN103781781B (zh) 2015-08-26
CR20140007A (es) 2014-05-14
NZ619001A (en) 2016-05-27
CO6852072A2 (es) 2014-01-30
JP2014520838A (ja) 2014-08-25
CL2014000079A1 (es) 2014-06-27
KR20140037915A (ko) 2014-03-27
NI201400002A (es) 2016-02-16
US8735413B2 (en) 2014-05-27
AR124688A2 (es) 2023-04-26
TWI659026B (zh) 2019-05-11
EP2731945A1 (en) 2014-05-21
SG10201605619XA (en) 2016-08-30
CA2841859C (en) 2021-03-09
MY180039A (en) 2020-11-20
DOP2013000308A (es) 2014-02-28
UY34191A (es) 2013-02-28
EP3255043A2 (en) 2017-12-13
ECSP14013130A (es) 2014-02-28
CU20140004A7 (es) 2014-05-27
AU2016244246A1 (en) 2016-10-27
EA027821B1 (ru) 2017-09-29
AU2012282316A1 (en) 2013-05-02
SI3255043T1 (sl) 2021-04-30
ZA201401059B (en) 2017-09-27
US9975881B2 (en) 2018-05-22
EP3255043B1 (en) 2021-01-20
AR087168A1 (es) 2014-02-26
CY1124329T1 (el) 2022-07-22
PE20181069A1 (es) 2018-07-04
PL3255043T3 (pl) 2021-07-12
PE20141944A1 (es) 2014-12-24
DK3255043T3 (da) 2021-03-29
HK1245779A1 (zh) 2018-08-31
CN103781781A (zh) 2014-05-07
AU2012282316B2 (en) 2016-07-14
TWI633098B (zh) 2018-08-21
BR112014000636B1 (pt) 2022-08-30
US20130040926A1 (en) 2013-02-14
RS61608B1 (sr) 2021-04-29
JP6006308B2 (ja) 2016-10-12
MX2013015085A (es) 2014-01-24
NZ719176A (en) 2017-11-24
IL230398A (en) 2017-10-31
ES2861927T3 (es) 2021-10-06
CA2841859A1 (en) 2013-01-17
MX342874B (es) 2016-10-17
HUE053703T2 (hu) 2021-07-28
TW201311670A (zh) 2013-03-16
MX353334B (es) 2018-01-09
TW201825479A (zh) 2018-07-16
JP2016190864A (ja) 2016-11-10
CU20160083A7 (es) 2017-03-03

Similar Documents

Publication Publication Date Title
EA201490077A1 (ru) N-(6-((2r,3s)-3,4-дигидроксибутан-2-илокси)-2-(4-фторбензилтио)пиримидин-4-ил)-3-метилазетидин-1-сульфонамид в качестве модуляторов рецептора хемокина
MX2014000536A (es) Compuestos de 4-piperidinilo para usarse como inhibidores de tanquirasa.
EA201170922A1 (ru) Производные сульфонамида
EA201490864A1 (ru) Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов
EA201590975A1 (ru) Ингибиторы prmt5 и их применение
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201690752A1 (ru) Ингибиторы g12c kras
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
EA202090486A2 (ru) Соединения для лечения спинальной мышечной атрофии
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
EA201201680A1 (ru) Морфолинопиримидины и их применение в терапии
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201590520A1 (ru) Фармацевтическая композиция с покрытием, содержащая регорафениб
UY34061A (es) Cocristales de ácido cítrico y l-prolina de (2s,3r,4r,5s,6r)-2-(3-((5-(4-fluorofenil)tiofen-2-il)metil)-4-metilfenil)-6-(hidroximetil)tetrahidro-2h-piran-3,4,5-triol
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201391288A1 (ru) Производные пиразолоспирокетонов для применения в качестве ингибиторов ацетил-коа-карбоксилаз
EA201692356A1 (ru) Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида
EA201491007A1 (ru) Лекарственные составы
EA201190293A1 (ru) Пролекарства триптолида
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
EA201391124A1 (ru) Новые бензодиоксолпиперазиновые соединения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG TJ TM